Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 41 recruiting now early-phase tilt

Brain Metastases: early-phase trial registry

41 of 68 indexed Brain Metastases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #203 of 28,707 conditions by registered trial count.

68 US clinical trials · 41 currently recruiting · #203 of 28,707 conditions by registered trial count

Brain Metastases: 68 US clinical trials tracked, 41 recruiting.

Brain Metastases is the subject of 68 registered US clinical trials on ClinicalTrials.gov, 41 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 48 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.

Enrollment posture brief

Registry condition brain-metastases

OPEN 41 | RECR 60% | LATE 3 | EARLY 48 | RANK #203 | SPON 7

Nearest open-share peer: Opioid Use Disorder (60% recruiting · 258 trials)

Diabetic Foot Ulcer61.8%Brain Metastases (this)60%Refractory Multiple Myeloma33.8%Stress Disorders, Post-Traum29.4%Acne Vulgaris2.9%
Open-enrollment share among volume-matched conditions near Brain Metastases

Brain Metastases lists 41 open slots (60% of 68 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Brain Metastases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Brain Metastases is recruiting above its size-band peers.

    41 of 68 indexed trials (60.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Brain Metastases trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 7 of 68 trials (10.3%). 45 distinct sponsors appear on at least one study for this condition label.

  3. Most Brain Metastases trials plan to enrol fewer than 100 people.

    Median target enrolment is 46 among the 68 trials that report a genuine target (sentinel values excluded). 53 of those (77.9%) plan for fewer than 100 participants.

  4. Brain Metastases research is mostly interventional.

    62 interventional and 6 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 122Phase 226Phase 32Phase 41

Open and recent trials

68 total, page 2 of 2

ACTIVE NOT RECRUITING Phase 2 21 participants

Study Assessing QBS72S For Treating Brain Metastases

Stanford University

NCT05305365

ACTIVE NOT RECRUITING Phase 1 21 participants

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Memorial Sloan Kettering Cancer Center

NCT04192981

ACTIVE NOT RECRUITING Early Phase 1 11 participants

A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

Memorial Sloan Kettering Cancer Center

NCT06209567

ACTIVE NOT RECRUITING Phase 1 2 participants

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Memorial Sloan Kettering Cancer Center

NCT06132945

COMPLETED Phase 1 84 participants

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

BBB-Therapeutics B.V.

NCT01386580

COMPLETED Phase 2 72 participants

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Angiochem

NCT02048059

COMPLETED Phase 2 65 participants

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Yale University

NCT02085070

COMPLETED 52 participants

MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy

University of Michigan Rogel Cancer Center

NCT02031237

COMPLETED Phase 2 50 participants

GliaSite 1-3 Mets Study

Hologic

NCT00589212

COMPLETED Phase 2 36 participants

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation

NCT02616393

COMPLETED Phase 1 29 participants

Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

EpicentRx

NCT02215512

COMPLETED Phase 2 20 participants

DM-CHOC-PEN for Brain Tumors in AYA Subjects

DEKK-TEC

NCT03668847

COMPLETED Phase 1 17 participants

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT00838929

COMPLETED Phase 1 14 participants

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

NCT03807765

COMPLETED NA 11 participants

Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases

Medical College of Wisconsin

NCT04545814

COMPLETED Phase 2 9 participants

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

Case Comprehensive Cancer Center

NCT02581839

COMPLETED Phase 1 9 participants

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

National Cancer Institute (NCI)

NCT01259479

COMPLETED 7 participants

CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases

University of Pittsburgh

NCT02058953

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 22
Phase 2 26
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Brain Metastases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Stereotactic Radiosurgery Radiation
6 trials
Pembrolizumab Drug
3 trials
Stereotactic Radiation Radiation
2 trials
Fractionated Stereotactic Radiation Therapy (FSRT) Radiation
2 trials
Memantine Drug
2 trials
Tucatinib Drug
2 trials
Stereotactic Radiosurgery (SRS) Radiation
2 trials
Cabozantinib Drug
2 trials

US sites by state

Facility locations filed on Brain Metastases trials. A trial with sites in several states counts in each.

Texas 15 trials
California 11 trials
Florida 10 trials
New York 9 trials
Ohio 7 trials
North Carolina 7 trials
Massachusetts 6 trials
New Jersey 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Brain Metastases page

68 registered trials, 41 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Metastases condition card totals 68 registered trials; most-linked intervention Stereotactic Radiosurgery; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.